EOC Pharma focuses on developing in-licensed oncology drugs for the China market. The company acquires or in-licenses cancer therapies and advances them through development in China. Its near-term plan, as reported, is to progress those in-licensed oncology candidates within China. The article reports a $71 million Series C financing to support that China-focused development. No operating metrics, revenue figures, pipeline details, or partnership names were disclosed in the article. EOC Pharma is a fast-growing, Shanghai-based biopharmaceutical company that in-licenses innovative global oncology products and develops, manufactures and commercializes them for China. The company has a pipeline of six novel products from global biopharmaceutical partners, including two innovative small molecules expected to enter Phase 3 registration studies in China in 2018 for breast cancer and gastric cancer. Its pipeline also includes innovative biologics being developed for indications in immuno-oncology and tumor metastasis. EOC is building a fully integrated manufacturing, development and commercialization platform and is a spin-off of the oncology division of Eddingpharm. The company plans to use new funding to advance its mid- and late-stage clinical pipeline and to in-license additional late-stage oncology assets. Management highlights a track record in strategic partnering and commercialization in China and intends to leverage an improved clinical and regulatory environment and a rapidly growing healthcare market.

Total raised

$103M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2019